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Rhesus macaques were studied to directly address the potential for plasmid-deficient Chlamydia trachomatis to serve as a live
attenuated vaccine in the genital tract. Five repeated cervical inoculations of rhesus macaques with wild-type serovar D strain
D/UW-3/Cx or a plasmid-deficient derivative of this strain, CTD153, resulted in infections with similar kinetics and induced
comparable levels of protective immunity. After all animals received five challenges with D/UW-3/Cx, levels of inflammation
observed grossly and histologically were similar between the groups. Animals in both groups developed evidence of oviduct dila-
tation; however, reduced oviduct dilatation was observed for “controllers,” i.e., animals without detectable chlamydial DNA in
the fimbriae at weeks 5 and 12. Grouping animals into “ascenders” and “controllers” revealed that elevated early T cell responses
were associated with protection, whereas higher antibody responses were associated with ascension. Protected animals shared
common major histocompatibility complex (MHC) alleles. Overall, genetic differences of individual animals, rather than the
presence or absence of the chlamydial plasmid in the primary infecting strain, appeared to play a role in determining the out-
come of infection.
Infections with the obligate intracellular bacterium Chlamydiatrachomatis are a major public health concern. In developing
nations, repeated conjunctival infections with serovars A to C
cause trachoma, the leading cause of preventable blindness world-
wide (1). Genitourinary infections with serovars D to K and L1 to
L3 are the most prevalent sexually transmitted bacterial infections
in the world. An effective vaccine is not available, and increased
screening and treatment have been associated with a rise in the
incidence of chlamydial genital tract infection (2). Although anti-
biotic therapy effectively eliminates infection, it does not reverse
established pathology. Serious sequelae resulting from genital
tract infection with Chlamydia include pelvic inflammatory dis-
ease (PID), ectopic pregnancy, chronic pelvic pain, and infertility
in women (reviewed in reference 3). Since the majority of infected
women are asymptomatic and do not seek treatment, the conse-
quences of infection often do not become apparent until years
after infection, when affected women are unable to conceive.
An effective immune response is required for resolution of
infection, but overly robust immune activation is responsible for
Chlamydia-induced pathology. Studies of mice and guinea pigs
have clearly demonstrated that innate immune responses cause
tissue damage, while CD4 T cells and antibody provide protec-
tion against challenge infection (reviewed in reference 4). Al-
though specific mediators of protection have been more difficult
to delineate for women, correlations between increased CD4 T
cell gamma interferon (IFN-) responses and reduced antichla-
mydial antibody levels have been associated with disease control
(reviewed in reference 4). The outcome of a chlamydial infection
results from an interplay between the host’s ability to control the
infection and the bacterium’s ability to simultaneously induce in-
flammation and subvert eradication.
A central regulator of Chlamydia-induced immunopathology
is the highly conserved 7.5-kb chlamydial plasmid (5–8). Mice
infected with plasmid-deficient Chlamydia muridarum exhibit
markedly reduced levels of immunopathology but develop an
adaptive immune response that prevents disease upon challenge
with virulent C. muridarum (5, 9). In addition, conjunctival inoc-
ulation of cynomolgus macaques with plasmid-deficient serovar
A has been shown to result in an abbreviated infection that pro-
tects against disease in a subset of animals challenged with the
virulent parental strain (7). In contrast, curing the plasmid in C.
caviae (10) and C. psittaci (11) did not result in significant changes
in virulence upon infection of guinea pigs and mice, respectively.
The protective capacity of plasmid-deficient strains has not been
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examined in a rhesus monkey model of Chlamydia genital tract
infection.
The rhesus monkey model of trachoma is distinct from the
genital tract model both in the mucosal site and in the adaptations
of Chlamydia to those sites. In the trachoma model, Chlamydia is
inoculated directly onto the conjunctiva, where disease develops.
In the genital tract model, Chlamydia is inoculated at the cervix
and ascends over time to the oviducts, the site of irreversible im-
munopathology. This delay in infection of the oviducts allows for
priming of Chlamydia-specific T cells and homing of those cells to
the genital tract, potentially affecting the dynamics of protection
and immunopathology. Genetic differences between ocular and
genital biovars may also differentially influence the pathogenesis
of infection in these models. C. trachomatis strains exhibit 99%
sequence homology, but genes differentially involved in tissue tro-
pism and immune evasion have been identified (reviewed in ref-
erence 12). For example, genital but not ocular biovars possess a
functional tryptophan operon that permits utilization of indole to
synthesize tryptophan (13, 14). This allows evasion of IFN--in-
duced tryptophan degradation by indoleamine 2,3-dioxygenase
(IDO) (13, 15). IFN- does not induce IDO in the genital tract
epithelium of mice (15, 16), which provides a further impetus to
explore the potential of plasmid-deficient Chlamydia to serve as a
live attenuated vaccine in higher-order mammals.
In the present study, we utilized a plasmid-deficient derivative
of C. trachomatis D/UW-3/Cx to infect rhesus macaques at the
cervix. This strain, CTD153, has an attachment/uptake defect and
induces lower levels of cytokine production in vitro and in the
murine genital tract (17). The aims of this study were to use the
rhesus monkey model of chlamydial genital tract infection to de-
termine (i) if a plasmid-deficient human C. trachomatis strain
induces pathology at lower rates than those of a fully virulent
strain, (ii) if “vaccination” with a plasmid-deficient strain is pro-
tective against subsequent challenge with a fully virulent strain,
and (iii) if immune correlates of protection can be identified. The
findings reported in this study are central to the future use of
plasmid-deficient Chlamydia strains as live attenuated vaccines.
MATERIALS AND METHODS
Strains, cell lines, and culture conditions. The C. trachomatis strain
D/UW-3/Cx (18) was obtained from the American Type Culture Collec-
tion (Manassas, VA) and plaque purified before use (19). The D/UW-
3/Cx strain was cured of the plasmid by novobiocin treatment to yield
CTD153 (17). The absence of the plasmid from CTD153 was previously
verified by PCR and glycogen staining (17). C. trachomatis L2/434/Bu was
also used where indicated. Bacteria were propagated in L929 cells (17) and
titrated by plaque assay (19) or as inclusion-forming units (IFU) (20),
using a fluorescently tagged anti-chlamydial lipopolysaccharide mono-
clonal antibody (Bio-Rad, Hercules, CA). Chlamydia elementary bodies
(EBs) were purified by centrifugation over a discontinuous gradient (21)
and inactivated by X-ray irradiation prior to use (17).
Animals. Ten young female rhesus monkeys (Macaca mulatta) (3.5
years of age; 4 to 5 kg) were included in the study. They were maintained
on a standard colony diet with fruit supplementation per the colony pro-
tocol. All procedures conformed to the requirements of the Animal Wel-
fare Act, and protocols were approved prior to implementation by the
Institutional Animal Care and Use Committee at the University of Cali-
fornia, Davis.
Infection and monitoring. Animals were divided into two groups
(n  5 animals/group) and were inoculated at the cervical os with the
human genital tract serovar D strain D/UW-3/Cx (group 1) or a plasmid-
cured derivative of this strain, CTD153 (group 2). After sedation with
ketamine hydrochloride (10 mg/kg body weight), they received 5 consec-
utive inoculations at the cervical os at 1-week intervals (week 0 to week 4),
with 1  106 IFU of either C. trachomatis D/UW-3/Cx (group 1) or
CTD153 (group 2) (Fig. 1). Vaginal swabs and sponges were obtained
each week, before inoculation, and were frozen at 80°C until use. At
week 5, the reproductive tracts were examined by abdominal ultrasound
followed by laparotomy. Gross pathology noted at laparotomy was re-
corded by an observer who was blinded to the experimental groups. The
fimbriae were gently swabbed for titration of Chlamydia. All monkeys
were subsequently challenged with 5 consecutive intravaginal inocula-
tions at 1-week intervals (week 7 to week 11), with 1  106 IFU of C.
FIG 1 Rhesus monkey inoculation protocol. Monkeys were assigned to two
experimental groups (n  5/group). Group 1 (animals 1 to 5) received 5
weekly intravaginal inoculations with D/UW-3/Cx (D). Group 2 (animals 6 to
10) received 5 weekly inoculations with the plasmid-deficient strain CTD153
(153). No inoculations were conducted at week 5 or 6, and then all animals
received 5 weekly inoculations with D/UW-3/Cx. Specimens were collected as
indicated. FIG 2 Bacterial burdens in the lower genital tract did not differ between
groups. For the first 5 weeks, group 1 (black bars) was inoculated with D/UW-
3/Cx, whereas group 2 (white bars) was inoculated with CTD153. All monkeys
were inoculated with D/UW-3/Cx for the last 5 weeks. Bars represent the
means 	 standard errors of the means (SEM) for log10 IFU/swab. Fractions
represent frequencies of monkeys that were positive for infection. Arrows in-
dicate weeks when monkeys were inoculated. P values were 0.05 on individ-
ual days and over the entire interval as measured via two-way RM ANOVA
with Bonferroni posttests.
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trachomatis D/UW-3/Cx. They were euthanized at week 12, and gross
pathology was evaluated by an observer who was blinded to the experi-
mental groups. The oviductal diameter was measured at the distal am-
pulla. The fimbriae were swabbed for titration of Chlamydia. Sections of
the fimbriae, oviducts, uterus, cervix, and lymph nodes were collected for
further analysis as described below.
Quantification of cytokines in vaginal secretions. An absorbent
sponge was inserted into the vaginal vault each week prior to infection and
then stored at 80°C prior to analysis. At analysis, sponge contents
were eluted as previously described (22). Levels of granulocyte colony-
stimulating factor (G-CSF), interleukin-17 (IL-17), IL-1
, IL-6, IL-8,




factor (GM-CSF), IFN-, IL-2, MIP-1, IL-2, tumor necrosis factor alpha
(TNF-), and IL-10 were assayed by using a multiplex cytometric bead
array (Millipore, Billerica, MA).
Flow cytometry and cytokine detection. Mononuclear cells were iso-
lated from the peripheral blood (PBMCs), iliac lymph nodes, and inguinal
lymph nodes by density gradient centrifugation, cryopreserved using a
controlled-rate protocol, and stored in liquid nitrogen until analysis. Cells
were cultured at a concentration of 5  105 cells per well, with or without
5 g/ml of D/UW-3/Cx EBs. After 5 days, the cells were stained with the
following antibodies from BD Biosciences (San Jose, CA) (unless other-
wise indicated): anti-CD3–fluorescein isothiocyanate (FITC) (clone
SP34), anti-CD4 –BV 605 (clone L200), anti-CD8 –phycoerythrin (PE)–
Texas Red (clone 3B5; Life Technologies, Grand Island, NY), anti-
CD28 –PE (clone CD28.2), anti-CD95–PE–Cy7 (clone dx2), anti-
NKG2A–allophycocyanin (APC) (clone z199; Beckman Coulter,
Indianapolis, IN), anti-CD69 –APC–Cy7 (clone FN50), anti-CCR7–peri-
dinin chlorophyll protein (PerCP)–Cy5.5 (clone 150503), and anti-
CXCR3–Alexa Fluor700 (clone 1C6/CXCR3). Cells were also stained with
a LIVE/DEAD Aqua Dead cell stain kit (Life Technologies). Cells were
permeabilized with a Cytofix/Cytoperm Plus kit according to the manu-
facturer’s instructions (eBiosciences, San Diego, CA) prior to staining
with anti-Ki67-V450 (clone B56). Raw cytometric data were acquired
with a BD LSRII flow cytometer and analyzed offline using FlowJo soft-
ware (Tree Star, Ashland, OR). The staining background was minimized
by using isotype controls of the antibodies used. Multifluorochrome
beads (Bang Laboratories, Fishers, Indiana) were used to calibrate cytom-
eters and to generate offline matrices for signal compensation to eliminate
electronic noise. The culture supernatants were harvested for measure-
ments of secreted IFN-, TNF-, and IL-2 by enzyme-linked immunosor-
bent assay (ELISA) (BD Biosciences).
PBMCs obtained from naive rhesus macaques were plated at 2  105
cells per well and stimulated with gradient-purified C. trachomatis
D/UW-3/Cx or CTD153 at a final concentration of 5 g/ml for 24 h.
The supernatants were collected and analyzed for IL-6, GM-CSF, and
IL-1
 production via a multiparametric assay (Bio-Plex; Bio-Rad,
Hercules, CA).
Lymph node ELISpot assay. IFN--specific enzyme-linked immu-
nosorbent spot (ELISpot) assays were performed on mononuclear cells
isolated from the iliac and inguinal lymph nodes by using a commercial
ELISpot kit according to the manufacturer’s instructions (monkey IFN-
ELISpot kit-ALP; Mabtech, Cincinnati, OH). Cells were cultured in du-
plicate wells (2  105 cells/well) for 24 h at 37°C and 5% CO2. Cells were
stimulated with anti-CD28 antibody (1 g/ml) (clone CD28.2; BD Bio-
sciences) in the presence or absence of inactivated D/UW-3/Cx EBs (2.5
g/ml). The spots were counted and quality controlled by using a CTL-
ImmunoSpot analyzer (C.T.L., Shaker Heights, OH).
Detection of antibodies in sera and vaginal secretions. Levels of
Chlamydia-specific IgA and IgG in sera and vaginal sponge eluates were
determined via ELISA at week 0 (negative control), week 6, and week 12,
as previously described (22). Plates were coated with inactivated serovar
L2/434/Bu EBs (2 g/ml), and antibody binding was detected with horse-
radish peroxidase (HRP)-conjugated anti-human IgG or IgA (Biolegend,
San Diego, CA).
FIG 3 The degree of resistance to repeated infections varied between individual monkeys. Four animals had no detectable bacteria after the first 2 weeks: two in
group 1 (animals 3 and 4) and two in group 2 (animals 6 and 7). Five animals appeared to develop an intermediate level of protective immunity in the lower genital
tract (animals 1, 2, 5, 8, and 9), and one animal did not develop resistance to infection (animal 10). Bars represent the log10 IFU/swab of the cervix each week.
Black bars represent titers resulting from the first five inoculations, which were performed with D/UW-3/Cx for group 1 and CTD153 for group 2. Striped bars
represent bacteria detectable after animals in group 2 were inoculated with D/UW-3/Cx.
Qu et al.
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PCR for amplification of chlamydial DNA. Fimbrial swabs obtained
at weeks 5 and 12 were thawed and vigorously vortexed. Cells were pel-
leted, and DNA was isolated according to the manufacturer’s protocol
(DNA isolation kit; Epicentre Biotechnologies, Madison, WI). Nested
PCR was used to detect ompA, using the primers and procedure described
by Bom et al. (23). Samples were considered positive for ompA if a band of
the appropriate size (614 bp) was visible after gel electrophoresis. Chla-
mydial DNA was quantified via real-time PCR analysis of the 16S rRNA
gene as previously described (24).
Detection of Chlamydia in the oviduct. Portions of the oviducts har-
vested at week 12 were stored in 500 l of sucrose phosphate glutamate
(SPG) buffer at 80°C until titration. Samples were thawed, minced
with scissors, and sonicated in a water bath for 5 min. Serial dilutions were
titrated via plaque assay; the limit of detection was 5 PFU per oviduct. An
aliquot was also removed for detection of the 16S rRNA gene by PCR as
described above (see “PCR for amplification of chlamydial DNA”).
Pathology. Gross findings were recorded at laparotomy at week 5 and
at tissue harvest (week 12). Visible erythema was scored as follows: mild, 1
or 2; moderate, 3 or 4; and severe, 5. Hematoxylin and eosin (H&E)-
stained sections of the ectocervix, endocervix, uterus, and oviducts were
assessed for the presence of acute inflammation (neutrophils), chronic
inflammation (lymphocytes/monocytes), and dilatation. The scoring sys-
tem used was as follows: 0, normal; 1, rare/minimal; 2, mild; 3, moderate;
and 4, severe. Histopathology was scored by a pathologist who was
blinded to the experimental design.
MHC genotyping. Major histocompatibility complex (MHC) class
I and class II DRB alleles were genotyped using 454 pyrosequencing
technology (Roche/454 Life Sciences, Branford, CT) as previously de-
scribed (25).
Statistics. Flow cytometry, cytokine, and bacterial burden data were
compared by using two-way repeated-measure analysis of variance (RM
ANOVA) with Bonferroni posttests. Genital tract pathology was com-
pared using the Mann-Whitney U test or one-way ANOVA with Dunn’s
multiple-comparison test. Antibody levels were compared by using one-
way ANOVA with Dunn’s multiple-comparison test. Proliferation and
cytokine production in the lymph nodes were compared using Student’s t
test. Where relevant, statistical analysis was conducted on the difference
between values obtained for cells cultured in the presence of EBs and those
simultaneously cultured in the absence of chlamydial EBs. Prism software
(GraphPad, La Jolla, CA) was utilized for all statistical analyses. P values
of 0.05 were considered significant.
RESULTS
Rhesus macaques infected with wild-type or plasmid-deficient
serovar D develop immunity to repeated infection. In this study,
we utilized a repeated infection approach that was previously
shown to induce oviduct disease in pig-tailed macaques (26). An-
imals were divided into two groups (n  5 animals/group) that
were inoculated at the cervical os five times on a weekly basis with
the human genital tract serovar D strain D/UW-3/Cx (group 1) or
a plasmid-deficient derivative of this strain, CTD153 (group 2)
(Fig. 1). After the first five inoculations, no inoculations were per-
formed for a period of 2 weeks. Animals in both groups were then
inoculated on a weekly basis for 5 weeks with D/UW-3/Cx.
No differences in bacterial burden in the lower genital tract
were found for animals in group 1 or group 2 on individual days or
over the course of infection (Fig. 2). All monkeys became infected,
and animals in both groups had titers of approximately 104 Chla-
mydia organisms at weeks 1 and 2. Reduced bacterial burdens
were noted beginning at week 3, with only 2 of 5 animals in
both groups being positive for infection at that time point (Fig.
2 and 3). Four animals appeared to develop complete resistance
to reinfection by week 3 (animals 3, 4, 6, and 7) (Fig. 3). Only
two animals, animals 9 and 10, had detectable chlamydiae over
the course of the last 5 weeks of infection with D/UW-3/Cx,
with animal 10 remaining positive through the end of the
study.


























1 1 NSF NSF 800 1,000 Right fimbria
edematous
4.0 3.0  ND
2 NSF NSF ND ND NSF 2.0 2.0 ND ND
3 NSF NSF ND ND Right oviduct
edematous
3.0 3.0 ND 
4 NSF NSF ND ND NSF 2.0 2.0 ND ND
5 Echogenic left ovary NSF 6,700 ND Fimbriae
edematous
3.5 3.0 ND ND
2 6 NSF NSF ND ND NSF 2.0 2.0 ND ND
7 NSF Erythema (score
of 4 out of 5)
ND ND Right oviduct
edematous
2.5 2.5 3,020 ND
8 Echogenic margin, left
ovary
NSF ND ND NSF 2.5 2.5 1,310 
9 Echogenic margin, right,
left ovaries
Erythema (score
of 4 out of 5)
3,700 ND NSF 2.0 2.0 760 ND
10 NSF Erythema (score
of 2 out of 5)
ND 12,000 Right oviduct
edematous
2.5 2.5 ND ND
a Genital tracts were analyzed via ultrasound and laparotomy at 5 weeks and at harvest (week 12). Fimbriae were swabbed at both time points. Chlamydia was found in swabs of the
fimbriae via nested PCR for all swabs for which the 16S rRNA gene was enumerated. Three swabs had chlamydial DNA detected only via nested PCR (). Shaded rows indicate
animals (animals 2, 4, and 6) with no detectable chlamydial DNA or evidence of gross pathology. Group 1, infected with D/UW-3/Cx and D/UW-3/Cx; group 2, infected with
CTD153 and D/UW-3/Cx. NSF, no significant findings; ND, not detected; , positive by nested PCR but not positive for the 16S rRNA gene.
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Detection of Chlamydia in the upper genital tract is associ-
ated with increased inflammation. Infection of the upper genital
tract was monitored by swabs of the fimbriae at laparotomy (week
5) and at tissue harvest (week 12). DNA isolated from swab eluates
was used as the template for a nested PCR assay targeting ompA
(23). At week 5, ompA-specific PCR products were detected via
agarose gel electrophoresis in samples obtained at laparotomy for
two animals in group 1 (animals 1 and 5) and two animals in
group 2 (animals 9 and 10) (Table 1). At week 12, DNA was again
detected in at least one oviduct from monkeys 1 and 9 and was also
detected for the first time in oviducts from monkeys 3, 7, and 8.
The chlamydial 16S rRNA gene was quantified via real-time PCR,
and although this test was less sensitive than ompA nested PCR,
the 16S rRNA gene was detected in 8 of 12 oviducts that had tested
positive for ompA (Table 1). There was no evidence of chlamydial
DNA in the fimbriae at week 5 or 12 for animal 2, 4, or 6. Live
bacteria were not detected in the oviductal sections collected at
tissue harvest for any monkey.
Upper genital tract inflammation and pathology were evalu-
ated at week 5 by abdominal ultrasound followed by laparotomy
and again at week 12. All animals with detectable chlamydial DNA
in the upper genital tract displayed abnormal findings at one of
these examinations (Table 1). Findings at week 5 included echo-
genic ovaries (animals 5, 8, and 9) and/or oviduct erythema (ani-
mals 7, 9, and 10). At tissue harvest, fimbrial (animals 1 and 5) or
oviductal (animals 3, 7, and 10) edema was observed for 5 of the
monkeys. We found no difference in the pattern of these findings
between group 1 and group 2. In addition, measurement of the
oviduct diameter at tissue harvest did not reveal differences
between the groups (Fig. 4A), with a median diameter of 3 mm
for animals in group 1 and 2.5 mm for animals in group 2.
However, when animals were separated into those that had
detectable DNA via PCR and abnormalities by gross examina-
tion, termed “ascenders” (animals 1, 3, 5, 7, 8, 9, and 10), and
those that had no detectable chlamydial DNA or pathology,
termed “controllers” (animals 2, 4, and 6), significant differ-
ences in oviduct diameter were observed (Fig. 4B) (P  0.01).
Dilated sections of oviducts were detected in two of the ascend-
ers (animals 1 and 9) on histopathology (Fig. 4C and D). All of
the “controllers” had an oviduct diameter of 2 mm, with no
evidence of dilatation (Fig. 4B).
Sections of the ectocervix, endocervix, uterus, oviducts, and
fimbriae were also examined for the presence of neutrophils and
mononuclear cells (lymphocytes/monocytes). Tissues from con-
trol rhesus macaques were obtained for comparison. Levels of
acute endocervical inflammation were increased for animals in
group 1 (median, 4) compared to those in group 2 (median, 2) and
uninfected animals (median, 0.5), although the differences were
significant only for the experimental groups compared to unin-
fected animals (P  0.05) (see Fig. S1A in the supplemental ma-
terial). Levels of acute and chronic inflammation were otherwise
very similar between these groups (see Fig. S1). When animals
were assessed as ascenders and controllers, inflammation levels
were also similar, although the median scores were consistently
0.5 to 1 point lower for the controllers (Fig. 5). In addition, ani-
mals classified as ascenders displayed higher inflammation scores.
FIG 4 Oviduct dilatation at week 12 was increased in monkeys with evidence of ascension of Chlamydia to the oviducts. (A) No significant difference in oviduct
diameter was detected after 5 weeks of challenge with D/UW-3/Cx between animals infected with D/UW-3/Cx for the first 5 weeks (group 1; black squares) and
animals infected with CTD153 for the first 5 weeks (group 2; white triangles). (B) The oviduct diameter was increased for monkeys who had detectable Chlamydia
in their oviducts (ascenders; black circles) at either week 5 or week 12 compared to monkeys with nondetectable levels of Chlamydia (controllers; white squares),
regardless of whether they were initially infected with D/UW-3/Cx or CTD153. Symbols represent individual oviducts. Horizontal lines indicate the medians. **,
P  0.01 by the Mann-Whitney U test for ascenders versus controllers. Hydrosalpinx was visible on histopathology (magnification, 4) on the right oviduct for
animal 1 (C) and on the left oviduct for animal 9 (D).
Qu et al.
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In particular, all 6 fimbriae that scored higher than 1 for neutro-
phils were from the ascender group (Fig. 5D). A similar trend was
observed for lymphocytes/monocytes, with 8 of 9 fimbriae
from the ascender group having scores higher than 1 (Fig. 5D).
A significantly higher score for mononuclear cells was noted
for ascenders (median, 1.5) than for uninfected animals (me-
dian, 0.5; P  0.05) (Fig. 5D). Dilated sections of the oviducts
were also detected on histopathology for two ascenders, i.e.,
animal 1 (right oviduct) and animal 9 (left oviduct) (Fig. 4C
and D). Dilation of the oviductal lumen was otherwise not
observed via histopathology. Despite the detection of inflam-
mation, none of the cytokines assayed in the genital tract secre-
tions were present at levels above those detected at week zero
(data not shown).
Chlamydia-specific antibodies serve as markers of increased
infection. Levels of IgG and IgA in sera and vaginal secretions
were measured at weeks 6 and 12. There was no difference in
antibody levels between group 1 and group 2 (see Fig. S2 in the
supplemental material). However, we detected a significantly
lower level of serum IgG at week 6 for controllers than for ascend-
ers (Fig. 6A) (P  0.05). Levels of IgA in the serum were detectable
for only 4 animals, all of which were in the ascender group (Fig.
6B). In the secretions, the two animals with the lowest level of
resistance to reinfection (animals 9 and 10) had the highest levels
of IgG (Fig. 6C) and were the only animals with detectable IgA
(Fig. 6D).
Early Chlamydia-specific T cell responses are associated with
enhanced control of infection, and late responses are associated
with increased infection. PBMCs isolated at weeks 0, 2, 4, and 12
were stimulated for 5 days in the presence and absence of chla-
mydial EBs. Proliferation was determined by upregulation of Ki67
(see Fig. S3 in the supplemental material). At week 2, the highest
levels of Chlamydia-specific proliferation by CD4 (Fig. 7A) and
CD8 (Fig. 7B) T cells were observed for the animals with the
greatest degree of infection control, i.e., animals 4 and 6 (Fig. 3).
Increased proliferation at weeks 4 and 12 was noted for animals
with poor control and continued infection (Fig. 7A and B), with
the highest levels observed for animal 10, the only monkey re-
maining infected over the entire study (Fig. 3). Consistent with the
increased proliferation for controllers at week 2, significantly in-
creased IL-2 levels were measured from the supernatants har-
vested at day 5 of stimulation (Fig. 7C). There were no significant
differences in PBMC IFN- production at any time point (Fig.
7D). When animals were grouped according to the initial strain of
infection, no significant differences were detected for CD4 T cell
proliferation (see Fig. S4A), CD8 T cell proliferation (see Fig.
S4B), or IL-2 production (see Fig. S4C). The only significant dif-
ference observed was increased IFN- production by PBMCs iso-
FIG 5 Histopathology of the genital tracts of ascenders and controllers at week 12. Genital tract tissues obtained from ascenders (A; black circles), controllers (C;
white squares), and uninfected controls (UI; black diamonds) at tissue harvest were analyzed histologically. (A) The highest levels of inflammation were detected
in the endocervix. Overall, inflammation was low in the uterus (B), oviducts (C), and fimbriae (D), although ascenders consistently exhibited the highest
inflammation scores. Horizontal lines indicate the medians. Symbols represent individual animals (A and B) or oviducts (C and D). *, P  0.05 by one-way
ANOVA with Dunn’s multiple-comparison test.
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lated from animals in group 1 at week 12 (see Fig. S4D). Stimula-
tion of naive PBMCs from three different animals with CTD153 (5
g/ml) resulted in slightly lower levels of cytokines than those
seen on stimulation with D/UW-3/Cx, but the differences were
not significant (data not shown). The average percent decrease for
PBMCs stimulated with CTD153 compared to those stimulated
with D/UW-3/Cx was 34% for IL-1
, 15% for IL-6, and 2% for
GM-CSF after 24 h.
TEM are increased in the peripheral blood of controllers,
while TCM are increased in that of ascenders. CD3
 T cells can be
subdivided into types of memory cells based on surface marker
expression. Central memory T cells (TCM) are CD28
 CD95,
and effector memory T cells (TEM) are CD28
 CD95 (see Fig. S5
in the supplemental material) (27, 28). The frequency of Chla-
mydia-specific CD4 TEM was significantly increased in the pe-
ripheral blood of controllers at week 2 (Fig. 8A), but no difference
in the frequency of CD8 TEM (Fig. 8C) was observed between
ascenders and controllers at any point. In contrast, CD4 TCM
(Fig. 8B) and CD8 TCM (Fig. 8D) frequencies were increased for
ascenders at week 4. We did not detect differences in the frequen-
cies of TEM or TCM between group 1 and group 2 (see Fig. S6).
Other parameters analyzed that did not differ between the groups
included CXCR3, CD69, and CCR7, as well as the frequency of NK
cells (CD3 CD8 NKG2a) (data not shown).
Analysis of Chlamydia-specific responses in the iliac lymph
nodes. Studies of mice have shown that Chlamydia-specific IFN-
-producing T cells are detectable in the iliac lymph nodes during
infection. Analysis of the frequency of CD4 (Fig. 9A) or CD8
(Fig. 9B) T cells proliferating in response to Chlamydia in the iliac
lymph nodes of ascenders and controllers at week 12 revealed
detectable responses but no difference between the groups. We
found a trend toward an increased frequency of cells producing
IFN- in response to Chlamydia in the iliac lymph nodes of con-
trollers at week 12 (Fig. 9C) (P  0.07). There were no differences
in the inguinal lymph nodes, and no differences were detected
when animals in group 1 and group 2 were compared (data not
shown).
Controllers share a subset of MHC class I and class II alleles.
Pyrosequencing was used to genotype the MHC class I A/B and
class II DRB loci (Table 2). We found that the two animals with the
greatest ability to control infection (animals 4 and 6) shared a total
of 10 MHC class I alleles and 3 MHC class II alleles. Animal 2, the
third monkey in the controller group, also shared four MHC class
I and one MHC class II allele with animals 4 and 6. Genes com-
pletely unique to animals in the controller group were the MHC
class 1B gene B049 and the class II DRB gene W2, which were
detected in animals 4 and 6 but not animal 2.
FIG 6 Levels of Chlamydia-specific IgG in sera and secretions were inversely associated with the degree of infection control. (A) Levels of IgG in sera were
significantly higher at 6 weeks for ascenders (black bars) than for controllers (white bars). There were no significant differences in levels of IgA in sera (B), IgG
in secretions (C), or IgA in secretions (D). *, P  0.05 by one-way ANOVA with Dunn’s multiple-comparison test. Bars represent the log2 values of the highest
antibody dilutions where antibody to chlamydial elementary bodies was detected at a level above that of the negative control (). The origin of the y axis was set
at the lowest dilution of the negative-control sample. Numbers on the x axis indicate animal numbers.
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DISCUSSION
In these studies, we directly addressed the potential for plasmid-
deficient C. trachomatis to serve as a live attenuated vaccine to
prevent genital tract infection and disease. Five repeated cervical
inoculations with wild-type serovar D strain D/UW-3/Cx and a
plasmid-deficient derivative of this strain, CTD153, resulted in
infections with similar kinetics and induced comparable levels of
protective immunity. After all macaques were challenged five
times with D/UW-3/Cx, similar levels of inflammation and pa-
thology were observed in both groups. However, grouping ani-
mals into “ascenders” and “controllers” based on the presence or
absence of chlamydial DNA in the fimbriae at weeks 5 and 12
revealed reduced oviduct dilatation as well as lower antichlamyd-
ial antibody titers and increased early T cell responses for “con-
trollers.” Thus, the characteristics of individual animals were the
key determinants of the outcome of infection, rather than the
presence or absence of the chlamydial plasmid in the strain used
for the first set of infections.
In contrast to the similar bacterial burdens we observed upon
inoculation with D/UW-3/Cx and CTD153 in these studies, both
human (8, 29) and murine (5) strains of plasmid-deficient Chla-
mydia are less infectious in the mouse model of genital tract infec-
tion. It is possible that we did not detect subtle differences in
infection that would have been observed in the first 6 days after
each inoculation, since endocervical swabs were obtained only
every 7 days. For example, in the mouse model, a reduced bacterial
burden was only detectable in the lower genital tract in the first
several days after infection with a plasmid-deficient strain of C.
muridarum (5). In addition, weekly inoculations would prevent
the detection of differences related to the duration of infection. In
the trachoma model, the infection course with plasmid-deficient
serovar A was significantly abbreviated (7). Lastly, differences re-
lated to the infectivity of the plasmid-deficient strain, as observed
for plasmid-deficient L2 (29) and serovar F (8) in mice, would
likely not have been detectable with repeated inoculations of 1 
106 organisms.
In mice, infection with plasmid-deficient C. muridarum does
not cause oviduct pathology and prevents the development of
immunopathology upon challenge with fully virulent C. muri-
darum (5). In the present macaque study, there were no differ-
ences in immunopathology between animals infected with plas-
mid-deficient serovar D and those infected with wild-type serovar
D for the first 5 weeks. At week 5, although only gross examina-
tions were conducted for pathology, 4 of 5 monkeys infected with
CTD153 for the first 5 weeks exhibited evidence of oviduct inflam-
mation. It is possible that differences in inflammatory infiltrates
would have been observed histologically or via flow cytometry at
week 5, but we did not obtain biopsy specimens at that time point
due to the potential for oviduct damage. In addition, none of the
animals developed evidence of severe disease over the 12-week
FIG 7 Chlamydia-specific responses were increased in the peripheral blood of controllers at week 2. Proliferation of CD3 CD4 T cells (A) and CD3 CD8
T cells (B) was determined by analysis of Ki67 expression by flow cytometry after 5 days of incubation with EBs. Levels of IL-2 (C) and IFN- (D) were measured
in the supernatants, with significantly higher levels of IL-2 detected in the supernatants of controllers (white squares; solid lines) than in those of ascenders (black
circles; dashed lines) at week 2. Data points indicate values obtained for PBMCs incubated with EBs for 5 days after subtraction of values for PBMCs incubated
without EBs. Horizontal lines indicate the means. **, P  0.01 by two-way RM ANOVA with Bonferroni posttests.
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course of the experiment, in contrast to the high degree of pathol-
ogy observed in the mouse model upon infection with Chlamydia
muridarum. It is possible that differences between plasmid-defi-
cient and wild-type C. muridarum are magnified in the mouse
model due to the highly virulent and pathogenic nature of C.
muridarum. In the current study, only two animals exhibited evi-
dence of tubal dilatation on histologic sections, and six animals
had grossly visible oviduct/fimbrial edema at the time of euthana-
sia. The frequency of these findings was consistent with that of
results described after 5 weekly cervical inoculations of rhesus
monkeys with a serovar E strain (26). In addition, a previous study
showed that after a single cervical inoculation with serovar D,
neither Chlamydia nor severe pathology was detected in the upper
genital tract of pig-tailed macaques (30). Repeated direct injection
of genital tract serovars into the oviducts was necessary to induce
severe disease, including adhesions, scarring, and systemic symp-
toms (31).
Although we did not detect differences between macaques
originally infected with CTD153 or D/UW-3/Cx, we did detect
interanimal variability in regard to the duration of lower genital
tract infection, presence of bacteria in the upper genital tract, and
degree of inflammation. We identified three animals that ap-
peared to be more resistant to upper genital tract infection/in-
flammation than the others. This is consistent with the findings
for the trachoma model, which showed that three monkeys previ-
ously infected with plasmid-deficient serovar A were protected
against disease to a greater extent upon challenge with wild-type
serovar A than the other three monkeys in the study (7). These
differences were attributed to variability in the MHC haplotype.
In addition, early studies of pig-tailed macaques revealed that the
FIG 8 Comparison of effector and central memory T cells in the peripheral blood of ascenders and controllers. Frequencies of Chlamydia-specific CD4 effector
memory cells (A), but not CD8 effector memory cells (C), were increased in the peripheral blood of controllers (white squares; solid lines) at week 2, while
frequencies of both CD4 central memory cells (B) and CD8 central memory cells (D) were increased in the peripheral blood of ascenders (black circles; dashed
lines) at week 4. TCM, CD28
 CD95 cells; TEM, CD28
 CD95 cells. Data points indicate frequencies obtained for PBMCs incubated with EBs for 5 days after
values for PBMCs incubated without EBs were subtracted. Horizontal lines indicate the means. *, P  0.05; **, P  0.01 (two-way RM ANOVA with Bonferroni
posttests).
FIG 9 T cell proliferation and IFN- production by mononuclear cells isolated from the iliac lymph nodes at week 12. Levels of proliferation of CD3 CD4 T
cells (A) and CD3 CD8 T cells (B), as determined by analysis of Ki67 expression by flow cytometry after 5 days of incubation with EBs, were similar for
ascenders and controllers. (C) Analysis of the frequency of IFN--producing cells in the iliac lymph nodes by ELISpot assay revealed a trend toward an increased
frequency in controllers at week 12 (P  0.07). Data points indicate values obtained for incubation with EBs for 5 days (A and B) or 24 h (C) after subtraction
of values obtained after incubation without EBs. Horizontal lines indicate the means. The data were analyzed via Student’s t test.
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degree of protective immunity that developed after resolution of a
single intravaginal inoculation with serovar D varied between an-
imals (30). Later studies found that MHC class I alleles were asso-
ciated with resistance and susceptibility to the development of
peritubal adhesions following multiple simultaneous inoculations
of the fimbriae and cervix with serovar D (32). Our genetic anal-
ysis did not detect any alleles that were exclusive to all three con-
troller monkeys, although we did detect an MHC class I allele and
an MHC class II allele that were present only in the two controllers
with the shortest course of lower genital tract infection.
Analysis of immune responses in the controller animals sug-
gested possible mechanisms of protection from disease. Findings
included a trend toward increased Chlamydia-specific CD4 and
CD8 T cells in the peripheral blood at week 2 and increased
numbers of IFN--producing cells in the iliac lymph nodes at
week 12. We also found a significantly increased level of Chlamyd-
ia-specific IL-2 production and a higher frequency of Chlamydia-
specific CD4 effector memory cells in the blood at week 2. Early
induction of these T cells likely allows for homing and establish-
ment of a protective population of Chlamydia-specific cells both
at the site of infection and in the draining lymph nodes. Genital
tract-resident memory CD4 T cells are protective in both the
murine herpes model and the murine chlamydial model of infec-
tion (33, 38). Detection of increased Chlamydia-specific responses
in animals with the highest levels of infection at later time points is
likely indicative of the development of an ineffective response that
did not effectively eliminate bacteria. This is also likely the case for
the detection of increased levels of antibody in animals that did
not effectively control infection. We have no data to suggest that
these T cell and antibody responses were harmful to the host. In
addition, future studies will be necessary to explore the protective
capacity of T cells and antibodies specific for individual chlamyd-
ial antigens. Our current study, involving 10 monkeys, was under-
powered to find significant differences in those parameters.
Over 95% of women infected with C. trachomatis are asymp-
tomatic, and although complications can be severe, they are rela-
tively rare (3, 34). Thus, the low degree of pathogenicity observed
for C. trachomatis in the rhesus monkey model mirrors human
infection more closely than infection of mice with C. muridarum,
although important differences remain. The animals in this study
TABLE 2 Summary of MHC class 1 and class II DRB pyrosequencing results for the rhesus macaques in this studya
aThe table shows the allelic diversity at the MHC class I and class II loci. Animals 2, 4, and 6 represent the “controllers.” Alleles shared by at least two of
the “controllers” are highlighted by unique colors. There were 5 alleles shared by all three animals in this group. The two most protected monkeys, with
the shortest duration of infection and no detectable bacteria in the fimbriae, shared 13 alleles, two of which were unique to these monkeys.
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were inoculated with a much higher bacterial load (1  106 IFU)
than what likely occurs during human sexual transmission (35).
Despite the high inoculum, four animals became culture negative
after 2 weeks, and infection resolved in all but one of the animals
by the end of the 12-week monitoring period. This contrasts with
observations in women, in whom untreated infection may con-
tinue for months to years (36, 37). The shorter duration of infec-
tion may explain why none of the animals developed marked
upper genital tract inflammation or disease. Nevertheless, nonhu-
man primates are important for examining the role of genetic
diversity in the immune response to C. trachomatis infection (7).
It is possible that the lab-passaged clonal C. trachomatis strains
used in this study were not optimal for producing disease and that
use of a low-passage C. trachomatis isolate obtained from women
with symptomatic infection may prove more virulent in ma-
caques.
The data presented here demonstrate that resistance to reinfec-
tion develops in the macaque genital tract after multiple challenge
infections irrespective of the presence or absence of the plasmid.
This study provides evidence against the use of plasmid-deficient
Chlamydia as a live attenuated vaccine for genital tract infection.
Our data indicate that early induction of Chlamydia-specific T
cells helps to control the ascension of bacteria to the upper genital
tract and thus prevents disease. Future studies will focus on iden-
tifying protective T cell antigens and testing vaccines in nonhu-
man primates with a diverse array of MHC haplotypes in order to
mirror the genetic diversity of humans.
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